Skip to main content
. 2022 Jun 22;12:881902. doi: 10.3389/fonc.2022.881902

Table 4.

Summary of adverse events reported in the study.

Placebo (N = 25) AHCC (N = 25)
Nausea 2 (8%) 1 (4%)
Bloating 1 (4%) 1(4%)
Heartburn 0 1 (4%)
fatigue 0 1 (4%)

All patients enrolled were included in safety analysis for adverse events. Overall, no study patients reported greater than grade 1 toxicity on either placebo or the AHCC supplement arm. AHCC was well tolerated compared to placebo.